novo_flag

Novo Nordisk’s Fiasp shows strong blood sugar control in under-18 type 1 diabetes patients

October 12, 2018
Medical Communications, Research and Development Fiasp, Novo Nordisk, Type 1 diabetes, diabetes, pharma

New data unveiled by Novo Nordisk has shown that its insulin injection Fiasp (fast-acting insulin aspart) could provide a better …

top_10_image

Top Ten most popular articles on Pharmafile.com this week

October 12, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing WHO, biosimilars. GSK, manufacturing, pharma, top 10

Politics played a big role in pharma this week after Trump introduced legislation aimed at reducing the price of drugs. …

trvn1

Trevena’s opioid injection fails to win over FDA committee

October 12, 2018
Medical Communications, Sales and Marketing FDA, Trevena, US, oliceridine, opioid, opioid crisis, pharma

Trevena has seen its opioid injection oliceridine fail to win over an FDA advisory panel in the management of acute …

Chanelle Pharma announces €86m investment over next five years

October 12, 2018
Medical Communications Ireland, chanelle, generics, investment, research

Chanelle Pharmaceuticals, one of the largest Irish-owned pharmaceutical companies in Ireland, have announced an €86 million investment programme over the …

USA struggles and middle income countries could do more in tackling health inequality according to Oxfam report

October 12, 2018
Medical Communications Latin America, USA, health, inequality, oxfam

A cluster of Latin American countries such as Costa Rica, Uruguay and Argentina, and a cluster of OECD countries with …

Living with Langerhans Cell Histiocytosis

October 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Langerhans Cell Histiocytosis, feature. pharma, patient experience, rare diseae

Affected as a young child by a rare disease which targets just one in 200,000 and led to neurodegeneration throughout …

roche__tree

Roche’s Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS

October 11, 2018
Research and Development Ocrevus, Roche, multiple sclerosis, pharma

Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in …

38254130862_0f3fa01db3_z

New US trade policy may limit foreign investment into biotechs

October 11, 2018
Research and Development CIFUS, Trump, america, biotech, capital, foreign investment

The US Trump Administration have issued new rules, which will put foreign investment into companies involved in the development and …

Sequiris invest £40m into expansion of Liverpool plant creating 100 new jobs

October 11, 2018
Manufacturing and Production, Research and Development Jobs, Vaccine, investment, liverpool

The Liverpool-based vaccine-maker Sequiris is investing £40 million into the expansion of its operations in the Speke area of Liverpool. …

image_readtop_2018_569751_15365546683454581

Celltrion’s Rituxan biosimilar gets unanimous backing from FDA committee

October 11, 2018
Sales and Marketing FDA, Oncologic Drugs Advisory Committee, Rituxan, Roche, Truxima

FDA approval looks to be in reach for Celltrion, as an advisory committee for the US regulator voted unanimously to …

29496564944_a9faceb1c2_z

Trump signs trust-busting biosimilar bill into law

October 11, 2018
Business Services, Sales and Marketing FTC, Trump, biosimilars, generics, us politics

President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of …

Manage Temperature Monitoring the EZ way with Woodley…

October 10, 2018
Investigational Medicinal Product, Temperature Monitoring, clinical trials

Manage Temperature Monitoring the EZ way with Woodley…As Clinical Trials protocols become ever more complex so too has the need …

psm_v46_d168_mesial_view_of_the_human_brain

Increased funding and research could help address unmet mental health needs

October 10, 2018
Research and Development funding, global data, mental health, research

Unmet needs relating to mental health could be met through increasing funding and research, according to data analytics firm GlobalData. …

NICE recommends first new X-linked hypophosphataemia therapy in over 30 years

October 10, 2018
Research and Development, Sales and Marketing Crysvita, Kyowa Kirin International, NHS, NICE, X-linked hypophosphataemia, pharma

NICE has announced its evidence-based recommendation that Kyowa Kirin International’s Crysvita (burosumab) be made available on the NHS for the …

Sackler-owned Mundipharma acquires biosimilar firm Cinfa Biotech

October 10, 2018
Research and Development Mundipharma, biosimilar, cinfa biotech, sackler

In a bid to strengthen their biosimilar portfolio, the Cambridge based pain management company Mundipharma has acquired biosimilar development firm …

novartis_outside_1

Novartis’ sickle cell drug reduces vaso-occlusive crises by 35% at Phase 2

October 10, 2018
Research and Development Novartis, crizanlizumab, pharma, sickle cell disease

Novartis has presented new Phase 2 data for its humanised anti-P-selectin monoclonal antibody crizanlizumab in the treatment of sickle cell …

14012226029_debf038610_z

WHO voices concern over British immigration policies after researchers refused entry

October 10, 2018
Research and Development WHO, academia, immigration, research, universities

The World Health Organization (WHO) has expressed concern over the UK’s immigration polices, after a number of academics were refused …

martin_van_trieste

Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO

October 9, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbot, Amgen, Bayer, civica rx, generic drugs, hospitals

Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen …

Menlo Therapeutics’ cough drug fails to meet primary endpoint in phase II trial

October 9, 2018
Manufacturing and Production Phase II, cough, menlo therapeutics, serlopitant

The Redwood City, California-based late stage biopharmaceutical company Menlo Therapeutics have announced that experimental drug serlopitant has failed to meet …

The Gateway to Local Adoption Series

Latest content